3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Myelodysplastic Syndromes
2
Leukemia, Myelomonocytic, Chronic
2
Anemia, Refractory, with Excess of Blasts
2
Pancreatic Neoplasms
1
Cytopenia
1
Interventions
Gemcitabine
74
Fluorouracil
31
Oxaliplatin
21
Leucovorin
21
130-nm albumin-bound paclitaxel
17
Capecitabine
14
Irinotecan
12
Albumin-Bound Paclitaxel
10
irinotecan sucrosofate
8
Radiotherapy
6
Taxes
5
Erlotinib Hydrochloride
5
folfirinox
4
rubitecan
3
Surgical Procedures, Operative
3
Specimen Handling
3
Pancreaticojejunostomy
3
Neoadjuvant Therapy
3
Drug Therapy
3
Cisplatin
3
Chemotherapy, Adjuvant
3
ruxolitinib
2
masitinib
2
dehydroftorafur
2
Saline Solution
2
S 1 (combination)
2
Paclitaxel
2
GV1001 peptide
2
Fentanyl
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pancreatic Neoplasms
×
ON 01910
×
Clear all
NCT01360853
2016-08-04
ONTRAC
Traws Pharma, Inc.
Phase 3
Completed
160 enrolled